Neonatal Syphilis

Overview

Definition

Neonatal syphilis, also known as congenital syphilis (CS), is a multi-system infectious disease caused by transplacental transmission of the spirochete Treponema pallidum from an infected mother to her fetus. The severity and clinical manifestations depend on the gestational age at transmission, duration of maternal infection, and adequacy of maternal treatment. It can lead to stillbirth, hydrops fetalis, prematurity, and a wide range of clinical signs in the neonate.

Epidemiology

The incidence of congenital syphilis in the United States has been rising dramatically since 2012, with a 754% increase between 2012 and 2021. In 2021, over 2,800 cases were reported, resulting in 220 stillbirths and infant deaths. Disparities exist, with higher rates observed among racial and ethnic minority groups, particularly Black, Hispanic, and American Indian/Alaska Native populations. This reflects broader sociodemographic inequities impacting access to prenatal care and sexually transmitted infection (STI) screening and treatment.

Classification

Congenital syphilis is broadly classified into: * Early Congenital Syphilis: Manifestations appearing from birth up to 2 years of age. * Late Congenital Syphilis: Manifestations appearing after 2 years of age.

Fetal manifestations can also be categorized: * Intrauterine Infection: Leading to hydrops fetalis, stillbirth, or prematurity. * Symptomatic Neonatal Syphilis: Clinical signs present at birth or within the first few weeks of life. * Asymptomatic Neonatal Syphilis: No clinical signs but serologic or CSF evidence of infection, or high suspicion based on maternal history.

Pathophysiology

Mechanism

Treponema pallidum is a motile spirochete that can cross the placenta at any stage of gestation, typically after 10-15 weeks, though early transmission is possible. The risk of transmission is highest during primary and secondary maternal syphilis (70-100%) due to higher spirochetemia. The risk decreases in early latent syphilis (40%) and late latent syphilis (8-10%). Once in the fetal circulation, T. pallidum disseminates to various organs, causing widespread inflammation, vasculitis, fibrosis, and necrosis, particularly affecting the liver, spleen, bone marrow, and central nervous system (CNS). The fetal immune response is often immature, leading to a diminished ability to clear the infection.

Risk Factors

• Untreated or inadequately treated maternal syphilis: This is the primary risk factor.
• Lack of prenatal care: Missed opportunities for screening and treatment.
• Maternal primary or secondary syphilis: Higher spirochetemia leads to higher transmission rates.
• Maternal HIV co-infection: May alter the natural history of syphilis, though its specific impact on vertical transmission rates is debated.
• Illicit drug use and homelessness: Associated with lack of prenatal care and increased syphilis exposure.
• Maternal infection acquired late in gestation: May result in serologically negative but infected neonates or rapid progression of disease.

Protective Factors

• Adequate maternal treatment: Penicillin G administered during pregnancy is highly effective in preventing transplacental transmission and treating fetal infection. Treatment should ideally be completed at least 30 days before delivery.
• Early and consistent prenatal care: Allows for timely screening and treatment of maternal syphilis.
• Universal screening: Routine syphilis screening recommended at the first prenatal visit, with repeat screening at 28-32 weeks gestation and at delivery for high-risk populations or areas of high syphilis prevalence.

Clinical Presentation

Signs and Symptoms

Cardinal Features

The clinical presentation is highly variable, ranging from asymptomatic infection to severe, life-threatening multi-organ disease affecting nearly every organ system.

Early Signs (Birth to 2 years)

• Cutaneous: Maculopapular rash (copper-colored, non-pruritic, often involving palms and soles), bullous lesions (pemphigus syphiliticus), perioral, perianal, and genital condyloma lata.
• Hematologic: Hepatosplenomegaly, hemolytic anemia, thrombocytopenia, leukocytosis.
• Skeletal: Osteochondritis, periostitis, resulting in pseudoparalysis (e.g., Parrot's pseudoparalysis due to painful long bone lesions), bone tenderness. Metaphysial lucencies or erosions on X-rays.
• Hepatic: Jaundice, elevated liver enzymes.
• Renal: Nephrotic syndrome (rare, due to immune complex deposition).
• Respiratory: Snuffles (rhinitis with blood-tinged, mucopurulent nasal discharge), highly infectious due to high spirochete load.
• Ocular: Choroidoretinitis, glaucoma (rare).
• CNS: Meningitis, hydrocephalus, cranial nerve palsies, seizures. Often asymptomatic at birth.

Advanced Signs (Late Congenital Syphilis, >2 years)

These result from persistent inflammation and tissue destruction. * Skeletal: Saber shins (anterior bowing of tibiae), saddle nose (destruction of nasal cartilage), Hutchinson's teeth (peg-shaped, notched permanent incisors), mulberry molars (enamel abnormalities of first molars), clutton's joints (symmetrical painless hydrarthrosis, especially of knees). * Ocular: Interstitial keratitis (leading to corneal opacification and blindness), salt-and-pepper fundus (choroidoretinitis scarring). * Ears: Sensorineural hearing loss (VIIIth cranial nerve deafness). * Neurological: Intellectual disability, seizures, juvenile paresis, tabes dorsalis (rare). * Other: Gummas (late destructive lesions), rhagades (linear scars radiating from mouth/nostrils).

Atypical Presentations

• Hydrops fetalis: Early, severe fetal infection leading to generalized fetal edema, ascites, pleural effusions, pericardial effusions.
• Stillbirth: Common outcome of severe untreated fetal infection.
• Prematurity and low birth weight: Non-specific but associated with congenital syphilis.
• Asymptomatic infection: Approximately 60-90% of infected neonates are asymptomatic at birth, making universal screening and careful evaluation crucial.

Physical Examination

Inspection

• Skin: Maculopapular rash (often on face, trunk, palms, soles), desquamation, bullae (pemphigus syphiliticus). Copper-colored lesions are characteristic.
• Mucous membranes: Rhinitis (snuffles), condyloma lata (if present in intertriginous areas).
• General appearance: Jaundice, pallor (due to anemia), poor feeding, irritability.
• Skeletal deformities: Pseudoparalysis (arm or leg held immobile due to painful periostitis/osteochondritis), frontal bossing.

Palpation

• Abdomen: Hepatosplenomegaly (common and often pronounced).
• Bones: Tenderness over long bones might indicate osteochondritis/periostitis.

Special Tests

• Neurological exam: Assess for cranial nerve palsies, signs of increased intracranial pressure (e.g., bulging fontanelle), seizures, muscle tone.
• Ophthalmologic exam: Fundoscopic exam for choroidoretinitis or "salt-and-pepper" retinopathy; direct inspection for interstitial keratitis if corneal opacity suspected.

Diagnostic Approach

The diagnosis of neonatal syphilis relies on maternal history, physical examination of the infant, serologic testing, and assessment of CSF, complete blood count (CBC), liver function tests (LFTs), and long bone radiographs.

History Taking

Key Questions

• Maternal RPR/VDRL titers during pregnancy: Date of testing, specific titers (e.g., 1:32 or non-reactive).
• Maternal treatment history: Drug, dose, date(s) of administration, gestational age at treatment, completion status.
• Maternal re-exposure risk: New exposures, untreated partners after maternal treatment.
• Maternal HIV status: Co-infection can impact clinical course (though no proven impact on treatment efficacy).
• Infant's symptoms: Any signs of rash, snuffles, poor feeding, irritability, jaundice, swelling.

Red Flags

• Maternal non-treponemal titer (RPR/VDRL) that is reactive and fourfold higher than the infant's non-treponemal titer.
• Mother received no treatment or inadequate treatment for syphilis.
• Mother treated with a non-penicillin regimen.
• Mother treated <30 days before delivery.
• Mother had signs of primary/secondary syphilis at delivery.
• Infant has any signs or symptoms suggestive of congenital syphilis.

Laboratory Tests

First-Line

• Infant Non-treponemal tests (RPR or VDRL):
  • Crucial Diagnostic Tool: These tests measure antibodies (reagin) produced by the body in response to tissue damage caused by T. pallidum.
  • Interpretation:
    • If infant's non-treponemal titer is fourfold higher than the mother's titer at delivery, it indicates active infant infection.
    • If infant's non-treponemal titer is the same or less than fourfold higher than the mother's, it most often reflects passive transfer of maternal antibodies. However, cannot rule out infection.
    • A non-reactive infant non-treponemal test generally rules out CS in asymptomatic infants, unless there is concern for acute infection acquired very late in gestation (window period) or maternal late latent syphilis.
  • Important: Use the same non-treponemal test (RPR or VDRL) for maternal and infant samples to allow for direct titer comparison.
• Infant Treponemal tests (TP-PA, FTA-ABS, EIA):
  • Measure specific antibodies to T. pallidum.
  • Interpretation: If reactive, it indicates exposure to T. pallidum, but cannot differentiate between maternal passive transfer and active infant infection. A reactive treponemal test alone does not confirm infection in the neonate. They are used primarily for confirmation of maternal infection.

Confirmatory (to establish infection and rule out neurosyphilis)

• Lumbar Puncture and Cerebrospinal Fluid (CSF) Analysis:
  • Required for ALL infants suspected of CNS involvement or with confirmed infection.
  • Parameters: Cell count (WBC >5 cells/mm³ is abnormal, PMNs in CSF often indicate bacterial meningitis), protein concentration (>100 mg/dL is abnormal in term infants, >150 mg/dL in preterm infants), CSF VDRL.
  • CSF VDRL: A reactive CSF VDRL is diagnostic of neurosyphilis, but a non-reactive CSF VDRL does not rule it out, especially in symptomatic infants or those with elevated CSF WBC/protein.
• Bone Marrow Aspiration: Rarely indicated, but can visualize spirochetes.
• PCR for T. pallidum: Can be performed on various specimens (blood, CSF, tissue) but not routinely available and sensitivity can be variable. Most useful for placental or autopsy tissue.
• Darkfield Microscopy: On suspicious lesions (skin, nasal discharge). Rapidly diagnostic if spirochetes are seen, but requires expertise and specialized equipment. Sensitivity is variable.

Monitoring

• Monitoring non-treponemal titers: Repeat every 2-3 months until they become non-reactive or a fourfold decrease is observed. This confirms adequate treatment and resolution of infection.
• CSF analysis: Repeat after treatment only if initial CSF was abnormal to confirm resolution of neurosyphilis.

Imaging

Recommended

• Long Bone Radiographs: Anteroposterior (AP) views of knees, ankles, wrists for all four extremities.
  • Findings: Can reveal osteochondritis, periostitis, metaphysial lucencies or erosions ("sawtooth" metaphyses), symmetric osteitis. These findings are diagnostic of congenital syphilis in the appropriate clinical context. Often seen in distal femurs, proximal tibiae, and humeri.

Advanced

• Cranial Ultrasound or MRI/CT of the Brain:
  • Indicated for: Infants with neurological symptoms (e.g., seizures, hydrocephalus), abnormal CSF findings, or severe systemic congenital syphilis.
  • Findings: Ventriculomegaly, periventricular calcifications, basal meningeal enhancement, cerebral vasculitis. Ophthalmological exam for choroidoretinitis or interstitial keratitis.

Management

Management decisions for neonatal syphilis are complex and depend on several factors, including maternal treatment history, infant's clinical presentation, and laboratory findings. The most recent guidelines from the Centers for Disease Control and Prevention (CDC) are critical.

Acute Management (Based on CDC 2021 Guidelines)

All infants born to mothers with reactive syphilis serology (even low titers or treated mothers) require evaluation and often treatment. The approach is categorized based on risk assessment.

Categories for Neonatal Syphilis Evaluation

Category 1: Definitive or Highly Probable Congenital Syphilis (Treatment duration: 10 days of IV penicillin)

• Definition: Infant has confirmed or highly probable congenital syphilis if any of the following are present:

  • Any abnormal physical examination finding consistent with congenital syphilis irrespective of maternal treatment.
  • Any reactive RPR/VDRL and a reactive treponemal test and infant's non-treponemal titer is equal to or greater than fourfold the maternal non-treponemal titer at delivery.
  • Positive darkfield microscopy or PCR of body fluids/lesions/placenta.
  • Abnormal CSF findings (WBC >5/mm³, protein >100 mg/dL in term infant, or reactive CSF VDRL).
  • Reactive CSF VDRL.
  • Radiographic evidence of congenital syphilis (e.g., osteochondritis).

• Immediate Interventions:

  • Perform a lumbar puncture (LP) for CSF analysis.
  • Obtain complete blood count (CBC) with differential and platelet count.
  • Order liver function tests (LFTs) and bilirubin.
  • Perform long-bone radiographs.
  • Perform an abdominal ultrasound to assess for hepatosplenomegaly or ascites.
  • Initiate IV Aqueous Crystalline Penicillin G immediately: 100,000-150,000 units/kg/day IV administered as 50,000 units/kg/dose IV every 12 hours for the first 7 days of life, then 50,000 units/kg/dose IV every 8 hours thereafter to complete a 10-day course.

Category 2: Asymptomatic Infants Born to Mothers with Inadequate or No Treatment (Treatment duration: 10 days of IV penicillin OR 1 dose of IM penicillin if specific criteria met)

• Definition: Infant is asymptomatic, has a non-reactive or stable/decreasing non-treponemal titer (equal to or less than fourfold the maternal titer at delivery), AND mother meets one or more of the following criteria:

  • Received no treatment.
  • Received inadequate treatment (e.g., non-penicillin regimen, incomplete penicillin course).
  • Received treatment <30 days before delivery.
  • Had evidence of relapse or re-infection after treatment.
  • No documentation of adequate treatment.

• Stabilization/Early Management:

  • Perform a lumbar puncture (LP) for CSF analysis.
  • Obtain complete blood count (CBC) with differential and platelet count.
  • Order liver function tests (LFTs) and bilirubin.
  • Perform long-bone radiographs.
  • Initiate IV Aqueous Crystalline Penicillin G for 10 days: 100,000-150,000 units/kg/day IV administered as 50,000 units/kg/dose IV every 12 hours for the first 7 days of life, then 50,000 units/kg/dose IV every 8 hours thereafter to complete a 10-day course.
  • Alternative (if all testing normal and reliable follow-up can be ensured): If all recommended evaluations (physical exam, CBC, LFTs, long bone X-rays, CSF analysis) are completely normal, and the infant is asymptomatic, a single dose of Benzathine Penicillin G 50,000 units/kg IM (max 2.4 million units) may be considered only if reliable follow-up is guaranteed. However, given the potential for missing subclinical neurosyphilis or other manifestations, a 10-day course of IV penicillin is generally preferred by many neonatologists in this high-risk group.

Category 3: Asymptomatic Infants Born to Mothers with Adequate Treatment (Treatment duration: Single dose of IM penicillin OR clinical/serologic follow-up)

• Definition: Infant is asymptomatic, has a non-reactive or stable/decreasing non-treponemal titer (equal to or less than fourfold the maternal titer at delivery), AND mother received adequate treatment (appropriate penicillin regimen for her stage of syphilis, completed >30 days before delivery, with a sustained decrease in non-treponemal titers).

• Management:

  • Option 1: Single dose Benzathine Penicillin G IM: 50,000 units/kg IM (max 2.4 million units). This is often chosen to cover for potential rare treatment failures or the possibility of acquiring infection late in gestation after maternal treatment.
  • Option 2: Clinical and Serologic Follow-up ONLY: If mother's non-treponemal titers were low and stable or declining after treatment, infant's titer is stable/declining, and highly reliable follow-up is assured, treatment may be withheld.

Category 4: Infants born to mothers who received adequate treatment and infant's RPR/VDRL is non-reactive (No treatment, routine follow-up)

• Definition: Infant is asymptomatic, mother received adequate treatment, AND infant's non-treponemal test is non-reactive.
• Management: No evaluation or treatment necessary for congenital syphilis.

Chronic Management (Follow-up)

Pharmacological

• Repeat Treatment: Only if warranted by incomplete resolution of non-treponemal titers, or recurrence of symptoms/abnormal labs.

Non-pharmacological

• Ongoing comprehensive developmental assessment: Due to potential for neurodevelopmental sequelae.
• Hearing and vision screening: Regular audiology exams until school age, and ophthalmology exams, especially if there were signs of ocular syphilis.

Monitoring

• Serologic Follow-up:
  • Repeat RPR/VDRL at 2, 4, 6, and 12 months (or until non-reactive).
  • Goal: The non-treponemal titer should decrease fourfold by 3 months of age and become non-reactive by 6-12 months of age.
  • Failure to decline (or increasing titer) indicates active, ongoing infection or treatment failure, and requires re-evaluation (including LP) and retreatment with a 10-day IV penicillin course.
• Clinical Follow-up: Regular pediatric visits to monitor for late manifestations of congenital syphilis.
• Repeat CSF analysis: If initial CSF was abnormal, repeat at 6-month intervals until normal to confirm resolution of neurosyphilis.

Treatment Algorithms

A simplified algorithm (always refer to the CDC 2021 STD Treatment Guidelines for full detail):

1. Maternal Syphilis Serology (RPR/VDRL) reactive?

   • No: No action for infant congenital syphilis (unless strong evidence of maternal primary syphilis with false negative serology).
   • Yes: Proceed to infant evaluation.

2. Infant Physical Exam (PE) consistent with congenital syphilis?

   • Yes (Symptomatic Infant):
     • Full workup: LP, CBC, LFTs, long bone X-rays.
     • Treat with Aqueous Crystalline Penicillin G 100,000-150,000 units/kg/day IV for 10 days.
   • No (Asymptomatic Infant): Proceed to next step based on maternal treatment history.

3. Maternal Treatment Adequate, Timely, and Documented? (Adequate: Penicillin G for appropriate stage, Timely: >30 days before delivery, Documented: Clear records).

   • Yes:
     • Infant non-treponemal titer fourfold higher than mother's?
       • Yes: Treat as Symptomatic Infant (Category 1).
       • No (infant titer < fourfold mother's):
         • Consider single dose Benzathine Penicillin G 50,000 units/kg IM.
         • OR observe with serial RPR/VDRL titers if confident in maternal treatment and follow-up.
   • No (Inadequate, No, or Unknown Maternal Treatment):
     • Infant non-treponemal titer fourfold higher than mother's?
       • Yes: Treat as Symptomatic Infant (Category 1).
       • No (infant titer < fourfold mother's):
         • Full workup: LP, CBC, LFTs, long bone X-rays.
         • If ALL workup is normal: Consider single dose Benzathine Penicillin G 50,000 units/kg IM if reliable follow-up.
         • Otherwise, or if any abnormality in workup: Treat with Aqueous Crystalline Penicillin G 100,000-150,000 units/kg/day IV for 10 days.

Refractory Cases

• Treatment failure: Defined as rising non-treponemal titers, persistence of symptoms or abnormal labs, or failure of titers to decrease fourfold by 6-12 months.
• Management: Re-evaluate thoroughly including repeat lumbar puncture, repeat imaging, and consider alternative diagnoses. Retreat with a full 10-day course of IV Aqueous Crystalline Penicillin G. Consult with pediatric infectious disease specialists.

Complications

Common

• Anemia: Often hemolytic.
• Thrombocytopenia.
• Hepatosplenomegaly.
• Osteochondritis/Periostitis: Leading to pseudoparalysis.
• Rash and snuffles.

Serious

• Neurosyphilis: Can lead to developmental delay, intellectual disability, seizures, hydrocephalus, and death.
• Stillbirth or Neonatal Death: Due to severe multisystem involvement, hydrops fetalis.
• Hydrops Fetalis: Life-threatening fetal condition.
• Hemorrhage: Due to severe thrombocytopenia.
• Blindness/Deafness: Due to interstitial keratitis, choroidoretinitis, or VIIIth nerve damage.

Long-term

• Skeletal deformities: Saber shins, saddle nose, Hutchinson's teeth.
• Sensory deficits: Interstitial keratitis (visual impairment), sensorineural hearing loss.
• Neurodevelopmental abnormalities: Intellectual disability, learning disabilities, behavioral problems, central nervous system disorders.
• Endocrine dysfunction: Rarely, hypopituitarism.

Prognosis

Factors

Prognosis is highly dependent on: * Timing of maternal treatment: Earlier treatment leads to better outcomes. * Completeness and adequacy of maternal treatment: Penicillin G is superior. * Severity of infant infection at birth: Asymptomatic infants have better outcomes than symptomatic infants. * Presence of neurosyphilis: Significantly worsens prognosis. * Timeliness and adequacy of infant treatment.

Survival

• Untreated congenital syphilis has a high mortality rate, estimated between 25% and 70%, including stillbirths.
• With early and adequate treatment, the survival rate is excellent, and most signs and symptoms resolve without long-term sequelae. However, CNS damage or severe organ damage (e.g., bone destruction) may be irreversible.

Quality of Life

• Most infants who receive timely and adequate treatment will have a normal quality of life.
• Unrecognized or inadequately treated cases, especially those with neurosyphilis, may suffer from significant long-term neurodevelopmental impairments, sensory deficits (vision, hearing), and skeletal deformities, severely impacting quality of life. Regular follow-up is crucial.

Prevention

Primary

• Universal prenatal syphilis screening: Recommended at the first prenatal visit for all pregnant women.
• Repeat screening: At 28-32 weeks gestation and again at delivery for women at high risk (e.g., residing in areas with high syphilis incidence, illicit drug use, multiple partners, new partners, incarcerated) or those living in communities with high syphilis prevalence.
• Prompt and adequate treatment of syphilis in pregnant women: Penicillin G is the only known effective treatment for preventing congenital syphilis. Non-penicillin regimens are not recommended.
• Screening and treatment of sexual partners: To prevent re-infection of the pregnant woman.
• Health education: Regarding safe sexual practices and STI prevention.

Secondary

• Early detection of congenital syphilis in neonates: Thorough evaluation of all neonates born to mothers with reactive syphilis serology, regardless of maternal treatment history.
• Prompt and adequate treatment of infected neonates: Following CDC guidelines to prevent serious early and late complications.

Tertiary

• Comprehensive follow-up care: For all infants treated for congenital syphilis to monitor for treatment response and long-term complications.
• Rehabilitation and supportive services: For infants with permanent sequelae (e.g., hearing aids for sensorineural hearing loss, developmental therapies).

Special Populations

Pediatric (Neonates and Infants)

• The primary focus of this document. Key is to differentiate passive maternal antibody transfer from active infection. Dose adjustments for penicillin are weight-based.
• Jarisch-Herxheimer Reaction: May occur after the first dose of penicillin, characterized by fever, rash, tachycardia, and respiratory distress. Usually self-limited but requires close monitoring and supportive care.

Pregnancy

• Diagnosis: All pregnant women should be screened. A reactive non-treponemal test should be confirmed with a treponemal test.
• Treatment: Penicillin G is the only effective treatment for preventing congenital syphilis and treating maternal syphilis during pregnancy.
  • Primary/Secondary/Early Latent: Benzathine Penicillin G 2.4 million units IM in a single dose.
  • Late Latent/Unknown Duration: Benzathine Penicillin G 2.4 million units IM weekly for 3 doses.
• Penicillin Allergic Pregnant Women: Should undergo penicillin desensitization, as alternative antibiotics (e.g., doxycycline, ceftriaxone) are not proven effective in preventing congenital syphilis.
• Monitoring after treatment: Repeat RPR/VDRL titers monthly in the third trimester. A fourfold decline is indicative of adequate response.

Comorbidities

• Maternal HIV Co-infection:
  • Diagnosis and treatment of syphilis in HIV-infected pregnant women are the same.
  • Some experts recommend monthly RPR/VDRL titers during pregnancy due to potential for altered immune response and higher rates of treatment failure/relapse.
  • Infants born to HIV-positive mothers with syphilis should still follow standard congenital syphilis evaluation and treatment guidelines.

Clinical Pearls

Diagnostic

• Always compare infant's non-treponemal titer to mother's at delivery, using the same test. A fourfold difference is key (e.g., mother 1:4, infant 1:16 is diagnostic of infant infection).
• Asymptomatic does NOT mean uninfected. The majority of infected neonates are asymptomatic at birth.
• Reactive treponemal tests in isolation are not diagnostic for congenital syphilis in neonates. They reflect maternal exposure and passive transfer.
• A "normal" CSF does NOT completely rule out neurosyphilis in a symptomatic infant or one born to a high-risk mother.
• Long bone radiographs are invaluable, easy to perform, and often reveal the first objective sign of infection in asymptomatic cases.

Treatment

• Penicillin is POWER: No other antibiotic is proven to prevent congenital syphilis or adequately treat fetal central nervous system infection.
• The 10-day IV penicillin regimen is the gold standard for confirmed or highly suspected congenital syphilis. Do not deviate without expert consultation.
• Do not restart the 10-day IV course if one dose is missed. Continue the regimen, but if >24 hours is missed, re-consult.
• Anticipate Jarisch-Herxheimer Reaction: Provide supportive care if it occurs after the first dose.

Pitfalls

• Misinterpreting infant serology: Assuming a positive RPR/VDRL in the infant always means infection without comparing to maternal titer.
• Inadequate follow-up: Failing to monitor serologic titers after treatment, leading to undetected treatment failure or relapse.
• Assuming maternal treatment is adequate: Always verify the specific drug, dose, and timing relative to delivery. Penicillin allergy desensitization or non-penicillin regimens are inadequate to prevent CS.
• Underestimating the asymptomatic presentation: Not performing full evaluations because the infant "looks well".
• Missing late-onset symptoms: Failure to counsel parents on signs of late congenital syphilis and importance of long-term follow-up for sensory and developmental screenings.

Recent Updates

Guidelines

• CDC 2021 STD Treatment Guidelines: These are the definitive resource for diagnosis and management of congenital syphilis in the US. Key updates include refined risk stratification for asymptomatic infants and clearer guidance on when a single IM penicillin dose versus a 10-day IV course is appropriate. The latest guidelines emphasize a more cautious approach, favoring 10-day IV penicillin for higher-risk asymptomatic infants, or where follow-up cannot be assured.

Evidence

• Ongoing research focuses on rapid prenatal syphilis diagnostic tests and point-of-care diagnostics to improve screening rates and reduce time to treatment, particularly in low-resource settings.
• Studies continue to monitor the rise in congenital syphilis rates and identify social determinants of health contributing to this increase.

Controversies

• Optimal management of asymptomatic infants with normal workup but high-risk maternal history and inability to ensure follow-up: While CDC offers options, many clinicians still lean towards the 10-day IV regimen in these scenarios due to concern for missed infection.
• Role of PCR in routine diagnosis: Still limited by availability and standardization, not yet a first-line diagnostic.
• Impact of maternal HIV on management: While HIV co-infection requires careful attention to maternal syphilis treatment response, current infant treatment guidelines remain the same.

Key References

Guidelines

• Workowski KA, Bachmann LH, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–189. (This is the primary and most authoritative source for managing congenital syphilis in the US).
• American Academy of Pediatrics. Syphilis. In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021–2024 Report of the Committee on Infectious Diseases. 32nd ed. Itasca, IL: American Academy of Pediatrics; 2021:733-745.

Studies

• Fukuda H, Kim S, et al. Clinical Manifestations and Outcomes of Congenital Syphilis: A Systematic Review and Meta-Analysis. Pediatrics 2018;141(5):e20172458.
• Karam G, et al. Congenital Syphilis: Still a Public Health Problem. Pediatr Clin North Am 2018;65(2):331-344.

Reviews

• Goldenberg RL, et al. Congenital Syphilis: A Global Perspective on the Problem and Potential Solutions. Clin Infect Dis 2020;71(Supplement_1):S1-S11.
• Centers for Disease Control and Prevention (CDC) - Congenital Syphilis Fact Sheets and Surveillance Reports. (Regularly updated data and useful summaries).

---

Disclaimer: This information is intended for educational purposes only and should not be used as a substitute for professional medical advice. Clinical decisions for individual patients must be made by qualified healthcare professionals based on complete medical history, physical examination, laboratory findings, and clinical judgment. Always refer to the most current guidelines from authoritative bodies such as the CDC for specific treatment recommendations.